PROPERTIES: Pharmacotherapeutic group: Drugs for treatment of bone diseases, bisphosphonates.Mechanism of action: Ibandronic acid is a highly potent bisphosphonate belonging to the nitrogen-containing group of bisphosphonates, which act selectively on bone tissue and specifically inhibit osteoclast activity without directly affecting bone formation. It does not interfere with osteoclast recruitment. Ibandronic acid leads to progressive net gains in bone mass and a decreased incidence of fractures through the reduction of elevated bone turnover towards premenopausal levels in postmenopausal women. INDICATIONS: Treatment of osteoporosis in postmenopausal women at increased risk of fracture.A reduction in the risk of vertebral fractures has been demonstrated. DOSAGE: For intravenous use ONLY. The recommended dose of ibandronic acid is 3 mg, administered as an intravenous injection over 15 - 30 seconds, every three months.